Bob Young: NCCN is a case study in keeping what works and discarding what doesn’t

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Robert C. Young, MD

Robert C. Young, MD

President, RCY Medicine, Past chairman of the board, National Comprehensive Cancer Network, Former chancellor and president, Fox Chase Cancer Center, Past chairman of the NCI Board of Scientific Advisors, Past president, the American Society of Clinical Oncology, the American Cancer Society, and the International Gynecologic Cancer Society.

We did something with guidelines that a lot of people have not done. And I personally continue to think that we have the right way to approach it and others feel very much differently.

The National Comprehensive Cancer Network, an organization that promulgates guidelines based on standards of care provided at academic institutions in the U.S., is indisputably one of the pillars of oncology today.

A quarter-century ago, NCCN was a startup dependent on cooperation between 13 elite institutions that were more comfortable competing with each other (The Cancer LetterMarch 15, 1996).

“One of the things that I would always say about the NCCN is that the NCCN has been much more successful than anybody ever imagined when they sat down and started it,” said Robert C. Young, founding vice chairman of the NCCN board and former president of Fox Chase Cancer Center.

“And I think the reason for that is that they’ve been willing to change their focus, and grow with their focus, and change the format and keep what works, and abandon what doesn’t. They’ve been able to evolve and successfully, and the whole basket of things that they do now is very different from what it started as, and many of the things were not envisioned at the time at all.

“And that’s the mark, I think, of a successful organization of any kind.”

Over the next two weeks, Cancer History Project will publish interviews with:

  • William T. McGivney, CEO from 1997 to 2012,
  • Robert W. Carlson, CEO since 2013.

The first story in the four-part series appeared last week (The Cancer LetterMarch 5, 2021).

Young, now a consultant, spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login